Subsequently, in the effector phase, the combined effect of CTLA-4 and PD-L1 inhibitors effectively overcomes the immunosuppressive “brake” exerted by tumor cells, thereby attaining a high level of activation and rapid elimination of tumor cells [40, 41]. The gene discussed is CTLA4; the disease is neoplasm.